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STRUCTURED ABSTRACT
Purpose of review—This review critically summarizes the evidence linking ultrafiltration (UF) 
rates to adverse outcomes among hemodialysis (HD) patients and provides research 
recommendations to address knowledge gaps.
Recent findings—Growing evidence suggests that fluid-related factors play important roles in 
HD patient outcomes. Ultrafiltration rate, the rate of fluid removal during HD, is one such factor. 
Existing observational data suggest a robust association between greater UF rates and adverse 
cardiovascular outcomes, and such findings are supported by plausible physiologic rationale. 
Potential mechanistic pathways include UF-related ischemia to the heart, brain, and gut and 
volume overload-precipitated cardiac stress from reactive measures to UF-induced hemodynamic 
instability. Inter-relationships among UF rates and other fluid measures such as interdialytic 
weight gain and chronic volume expansion render the specific role of UF rates in adverse 
outcomes difficult to study. Randomized trials must be conducted to confirm epidemiologic 
findings and examine the effect of UF rate reduction on clinical and patient-centered outcomes.
Summary—Compelling observational data demonstrate an association between more rapid UF 
rates and adverse clinical outcomes. Before translating these findings into clinical practice, 
randomized trials are needed to verify observational data results and to identify effective strategies 
to mitigate UF-related risk.
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Mounting evidence linking fluid-related factors and outcomes among maintenance 
hemodialysis (HD) patients has stirred debate about optimal fluid management practices. 
Dialysis leaders have implored providers to consider fluid-related factors alongside 
clearance metrics and patient well-being in adequate HD determination.(1) Absence of 
objective volume status assessment tools and lack of fluid-related clinical trials have led to 
controversy regarding ideal fluid management standards. Ultrafiltration (UF) rate, the rate of 
fluid removal during HD, has been put forward as a potential actionable component of fluid 
management (Figure 1).(2, 3) Observational studies have demonstrated associations between 
more rapid fluid removal and greater morbidity and mortality, leading some experts to call 
for adoption of ceiling UF rate thresholds.(2) The objectives of this commentary are to: 1) 
critically review the UF rate and outcome evidence, 2) consider potential mechanistic 
pathways and mitigation strategies for UF-related harm and 3) identify knowledge gaps.
ULTRAFILTRATION RATE AND OUTCOME EVIDENCE
Three observational studies have demonstrated associations between greater UF rates and 
mortality. Using the Dialysis Outcomes and Practice Patterns Study cohort, Saran, et al. 
found an association between UF rates >10 mL/h/kg and higher all-cause mortality (adjusted 
HR 1.09, p=0.02).(4) Surprisingly, the authors found no association between higher UF rates 
and cardiovascular mortality. This analysis was followed by an Italian study in which 
Movilli et al. demonstrated that for every 1 mL/h/kg increase in UF rate, there was a 22% 
increase in mortality risk (p<0.01). In secondary analyses, authors identified a UF rate of 
12.4 mL/h/kg as the most discriminatory cut-point for predicting two year mortality.(5) In a 
post-hoc analysis of the HEMO Study, Flythe et al. employed a UF rate threshold of 13 
mL/h/kg, finding that patients with UF rates >13 mL/h/kg had a 59% increased risk of all-
cause mortality and 71% increased risk of cardiovascular mortality (p<0.001 for both). UF 
rates 10–13 mL/h/kg were not associated with outcomes in the full cohort but were among 
patients with heart failure. When UF rate was considered as a spline, UF-associated risks 
were shown to rise markedly between 10 and 13 mL/h/kg.(6)
To date, there have been no clinical trials evaluating the effect of UF rates on outcomes. We 
are left to interpret and apply observational data, but in doing so, must be mindful of their 
limitations. Residual confounding is an inherent limitation of observational studies. Even the 
most optimally composed models cannot fully account for all confounding. Confounders are 
factors associated with both the exposure of interest and the outcome and are not factors 
recognized as intermediaries along the causal pathway between exposure and outcome.(7) 
All three UF rate studies included numerous potential confounders as covariates in 
multivariable analyses, but consideration of residual confounding from 1) unmeasured 
patient health status, 2) selective HD treatment prescription practices and 3) residual kidney 
function is warranted. All UF rate studies included markers of health such as albumin, blood 
pressure, and co-morbidities, but these variables fall short in fully capturing patient 
resiliency, leaving open the possibility of residual confounding from health status. Second, 
frailer patients may receive shorter treatments due to prior HD intolerance or a lower body 
weight-conferred ability to achieve clearance benchmarks in shorter time. Additionally, 
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shorter sessions may be selectively prescribed to non-adherent patients with histories of 
early HD termination. Thus, patients with longer treatment times (TTs) and associated lower 
UF rates may be healthier. Flythe et al. accounted for confounding from HD intolerance by 
employing prescribed rather than delivered TT, but this approach does not address 
confounding from selective HD prescriptions. In a separate analysis, Flythe et al. examined 
TT and outcomes among patients with adequate urea clearance matched on body weight, 
finding that patients with longer TTs had better survival than patients of the same weights 
with shorter TTs.(8) While this study did not directly address UF rates, it suggests that 
slower fluid removal facilitated by longer TTs may be advantageous independent of body 
weight.
Third, confounding from residual kidney function must be considered. Greater residual 
kidney function is associated with better clinical outcomes.(9) Patients requiring greater UF 
rates often have less native kidney function, rendering statistical control for urine output 
critical. Saran et al. did not consider residual kidney function in their analyses.(4) Flythe et 
al. included a binary variable (urine output ≤ versus >200 mL/day).(6) This is a coarse 
dichotomy. Patients with 2000mL urine/day may have better outcomes than patients with 
250 mL urine/day, a difference not accounted for by Flythe et al. In contrast, Movilli et al. 
restricted study to patients with urine output ≤ 150 mL/day. This study provides the most 
compelling support for the UF rate—outcome association absent confounding from residual 
kidney function.(5)
Analytical decisions should also be considered when weighing observational data. All 3 
studies considered UF rates as baseline mean values. Movilli et al. employed a mean UF rate 
over 30 days (approximately 13 treatments) and Flythe et al. used the mean UF rate in the 
HEMO Study pre-randomization period (1–4 treatments).(5, 6) Saran et al. also used a mean 
but did not report the number of treatments considered.(4) Arithmetic means are sensitive to 
extreme values. Outlier values for UF rate will have a greater influence in means derived 
from relatively few treatments, and thus may alter outcome associations. Additionally, when 
using a single, time-fixed mean UF rate as the exposure, the corresponding implicit 
assumption is that each individual’s UF rate during follow-up is equivalent to the mean UF 
rate captured at baseline. In reality, UF rates are dynamic and fluctuate with TT and 
interdialytic weight gain (IDWG) changes, both factors altered by ambient health status. 
Related, none of the existing studies considered time-varying confounders. Studies 
employing UF rate as a time-varying exposure and considering time-varying confounders 
would enhance the evidence base.
Finally, Flythe et al. have been criticized for including IDWG in their multivariable models, 
as IDWG is highly correlated with UF rate. (2, 3, 6) Similar choices were made in the two 
other UF rate studies with Movilli et al. including IDWG and Saran et al. including 
intradialytic weight loss in models. Collinearity between UF rate and IDWG could lead to 
unreliable effect estimates from model imprecision. In repeat analyses of the HEMO Study 
without multivariable model inclusion of IDWG, Flythe et al. report similar magnitudes of 
association between UF rates and outcomes, providing reassurance that estimates were 
minimally affected by IDWG inclusion (unpublished).
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Although existing observational data have potential short-comings, the demonstrated UF 
rate—outcome association is supported by evidence from mechanistic studies. Such studies 
point to UF-induced hypo-perfusion of vital vascular beds as outcome mediators (Figure 2). 
UF-induced intravascular volume depletion diminishes coronary blood flow, leading to 
cardiac ischemia as evidenced by myocardial wall stunning on echocardiography and 
troponin elevation.(10–12) Repetitive cardiac ischemia leads to ventricular remodeling and 
downstream effects of heart failure and arrhythmia.(13, 14) Recurrent HD-induced 
myocardial stunning has been linked to greater ejection fraction declines.(11) Dialysis 
patients are especially vulnerable to reduced myocardial oxygen supply due to a high burden 
of small vessel disease and high oxygen-requiring, hypertrophied ventricles. Notably, more 
frequent HD, a schedule characterized by lower IDWG and UF rates, is associated with 
reduced myocardial stunning.(15) Collectively, this data support greater UF rates as a 
contributor to adverse cardiovascular outcomes.
UF-induced ischemia is not limited to the heart and likely impacts both the brain and gut. 
Chronic cerebral hypo-perfusion among HD patients has been linked to white matter 
changes, dementia, and depression.(16) Cooled dialysate may improve white matter changes 
via vasoconstriction.(17) Additionally, UF-induced gut ischemia may lead to bacterial 
translocation from the gut to the bloodstream. Increased blood endotoxin has been 
associated with cardiac stunning, and more frequent HD regimens are associated with lower 
endotoxin levels.(18, 19) HD-induced endotoxemia represents a plausible link between 
intradialytic hemodynamics and chronic inflammation.(18, 20)
Beyond its direct end-organ effects, UF-induced hypotension and cramping (UF-related or 
not) may result in interventions with unintended, deleterious consequences. Such events 
often leads to early UF termination, halting fluid removal before the target weight can be 
achieved, thereby introducing harm from volume overload. Over time, target weights may 
be adjusted upward to match post-dialysis weights, leaving patients chronically volume 
expanded. Chronic volume expansion has been linked to adverse cardiovascular outcomes 
through ventricular hypertrophy and fibrosis and eventual heart failure and arrhythmias.(13, 
21–23) Not surprisingly, recent data link more frequent missed target weights to adverse 
cardiovascular outcomes.(24, 25) In addition to HD truncation, hypotension or patient 
cramping may lead to normal or hypertonic saline administration. These interventions put 
patients at risk for failed target weight achievement, greater IDWG from positive sodium 
balance, and exacerbated hypervolemia.(26, 27)
ULTRAFILTRATION RATE: RISK MARKER OR INDEPENDENT RISK 
FACTOR?
While the proposed physiologic link between rapid UF rates and outcomes is compelling, 
UF rate is a composite metric, dependent on two factors: IDWG and TT. Both factors have 
been independently associated with greater mortality, and both are plausible drivers of the 
UF rate—outcome association. Prior studies have shown that greater amounts of IDWG 
associate with adverse outcomes in a dose-response pattern.(28–30) Volume overload from 
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frequent high IDWG can lead to maladaptive cardiac structural changes. Additionally, 
intradialytic hypotension is more prevalent among patients with greater IDWG.(31) More 
frequent intradialytic hypotension is associated with all-cause and cardiovascular mortality.
(31, 32) Thus, it is plausible that either volume overload or end-organ damage from 
intradialytic ischemia drive the observed UF rate—outcome association. Similarly, shorter 
TT has been linked to greater mortality in observational studies across various cohorts using 
a variety of methodologies.(4, 8, 33, 34) Shorter TT may impact mortality through both 
clearance and volume pathways, making TT a plausible mediator of the UF rate—outcome 
association.
Flythe et al. explored the roles of TT and IDWG in the UF rate—outcome association by 
matching patients with identical IDWGs and examining the TT and mortality association, 
and then, separately, matching patients with identical TTs and examining the IDWG and 
mortality association. The authors excluded patients not meeting Kt/V standards to limit 
confounding from clearance. Findings demonstrated that both TT and IDWG play 
significant roles in the UF rate—mortality association, independent of one another.(35) 
Finally, the role of chronic volume expansion in UF-related outcomes must be considered. 
Rapid UF rates indirectly contribute to chronic volume expansion when HD is terminated 
early, UF rates decreased, or target weights adjusted upward due to cramping or 
hypotension.
It is certainly physiologically plausible that greater UF rates are independent risk factors for 
morbidity and mortality, but, it is also conceivable that their harm stems from hypervolemia, 
rendering them surrogate risk markers. Existing data do not allow us to fully distinguish the 
individual influences of UF rate, IDWG, TT, and chronic hypervolemia on outcomes. 
Evidence supporting these fluid-related factors as critical contributors to adverse outcomes 
is strong, but the optimal approach to reducing their risks is less obvious due to measure 
inter-relationships.
INTERVENTIONS TO REDUCE ULTRAFILTRATION RISK
Ultrafiltration rate reduction is achieved by IDWG decrease or TT extension. Dietary 
restrictions, with salt restriction of greater import than fluid restriction, are physiologically 
sound approaches to IDWG reduction; however, patients are poorly adherent. In a survey of 
over 400 patients prescribed fluid restrictions, >40% reported non-adherence on a near-daily 
basis.(36) Psychological and behavioral interventions may improve adherence, but 
sustainability of these efforts has not been studied.(37–39) Use of lower dialysate sodium is 
an additional method for curbing IDWG. However, this intervention remains controversial 
as observational studies of the dialysate sodium--mortality association have yielded mixed 
results.(40–42) Diuretics may lessen IDWG among patients with residual kidney function, 
but this approach has not been evaluated. Dialysis prescription changes such as increased 
HD frequency to reduce IDWG and TT extension to allow for more gradual fluid removal 
are other options, but patients are generally averse to more frequent and longer HD. Flythe 
et al. surveyed 600 HD patients and found that only 12% were willing to add a 4th weekly 
treatment and 21% were willing to increase TT by 30 minutes in exchange for liberalized 
fluid intake.(36)
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Some experts have suggested imposing UF rate thresholds (such as 13 mL/h/kg) to reduce 
UF-related risk.(2, 3) Patients presenting with fluid gains requiring UF rates above the 
threshold would require TT extension or additional treatments. Patients declining TT 
extension would have UF rates capped, leaving them above their prescribed target weights at 
HD conclusion. While it is plausible that the mere mention of TT extension would motivate 
patients to limit IDWG, it is equally plausible that UF needs would remain unchanged and 
patients declining TT extension would become volume-expanded. Rigorous investigation of 
the effect of UF rate thresholds on volume status, fluid-related hospitalizations and other 
adverse outcomes including patient-centered outcomes are needed prior to threshold 
adoption. Other potential treatment changes to reduce rapid UF rate harm include chilled 
dialysate, UF profiling (decelerating UF rate to match declining plasma refill rate) and 
sequential dialysis (isolated UF followed by combined HD and UF). These methods have 
been incompletely studied and their effects on cardiac stunning, target weight achievement, 
and cardiovascular outcomes are unknown.
KNOWLEDGE GAPS
The relative importance of UF rate, IDWG, TT, and chronic volume expansion to clinical 
outcomes is unknown. In cases of high weight gain or chronic volume expansion, clinicians 
face the conundrum of choosing between rapid fluid removal and a “dry” patient and slower 
fluid removal and a “wet” patient. It is plausible, and in the authors’ opinions, likely, that 
exposure to high UF rates for isolated time periods in the name of target weight achievement 
or challenge is preferable to low UF rates and unchallenged, hypervolemic states. Existing 
data do not allow us to make these distinctions. Imposing UF rate thresholds without 
understanding their effect on other fluid measures is premature. Prospective study of these 
issues is needed before optimal fluid standards can be incorporated into quality programs.
Additionally, we lack prospective trial data confirming the effects of fluid-related factors on 
morbidity and mortality. Such studies should evaluate not only cardiovascular endpoints but 
also patient-reported outcomes including intradialytic symptoms, recovery time, and quality 
of life. We must place greater emphasis on identifying UF rate mitigation strategies that are 
acceptable to patients. Patient-dependent strategies like dietary restrictions and willingness 
to extend TT have proven unsuccessful. Increased focus on HD procedural alterations such 
as cooled dialysate and different fluid removal patterns may be prudent, but remain 
understudied. Finally, objective measures of volume status are needed. Improved accuracy 
in determining total-body euvolemia would obviate the need for target weight probing (with 
or without high UF rates) and would limit sub-clinical hypervolemia.
CONCLUSION
Observational data suggest an association between greater UF rates and mortality among 
HD patients. Recurrent end organ hypoperfusion and its downstream consequences of 
cardiac remodeling, brain white matter damage, and gut-related systemic endotoxemia are 
possible mechanisms underlying these associations. Despite the plausible and observational 
data-supported association between rapid UF rates and outcomes, we lack randomized trials 
confirming these findings. In conducting such trials, patient strategy acceptance must be 
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given high priority as clinical trials will be for naught, if patients are unwilling to adopt the 
identified, evidence-based intervention.
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• Existing data provide compelling evidence linking more rapid fluid removal and 
greater mortality, but these studies are limited by inherent shortcomings of 
observational data.
• Both overt and subclinical hypo-perfusion of vital organs including the heart, 
brain, and gut are plausible mediators of the observed association between 
greater ultrafiltration rates and adverse outcomes.
• Prior to establishing ultrafiltration-based quality metrics, clinical trials 
evaluating the effect of ultrafiltration rate thresholds on clinical outcomes is 
needed.
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Potential mechanisms underlying the ultrafiltration rate and adverse outcome associations.
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